Related Experiment Video
Updated: Feb 22, 2026
07:20
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
2.0K
Therapy of highly active pediatric multiple sclerosis.
Peter Huppke1, Brenda Huppke1, David Ellenberger2
1Department of Pediatrics and Pediatric Neurology, University Medical Center Göttingen, Georg-August-Universität Göttingen, Göttingen, Germany.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|September 22, 2017
Summary
Pediatric multiple sclerosis (MS) is often highly active. Treatments like natalizumab (NTZ) and fingolimod (FTY) significantly reduce disease activity and improve outcomes in children with MS.
Area of Science:
- Neurology
- Pediatric Neurology
- Immunology
Background:
- Pediatric multiple sclerosis (MS) presents unique challenges in diagnosis and management.
- Understanding the frequency of highly active disease in children is crucial for effective treatment strategies.
Purpose of the Study:
- To determine the prevalence of highly active disease in pediatric MS.
- To evaluate the efficacy of natalizumab (NTZ) and fingolimod (FTY) in treating pediatric MS.
- To assess the impact of modern treatment approaches on the long-term clinical course of pediatric MS.
Main Methods:
- Retrospective single-center study conducted at the German Center for MS in Childhood and Adolescence.
- Analysis of 144 pediatric MS patients diagnosed between 2011 and 2015.
- Evaluation of treatment response to natalizumab (NTZ) and fingolimod (FTY), including relapse rates, new T2 lesions, and contrast-enhancing lesions.
Main Results:
- Over 40% of pediatric MS patients exhibited highly active disease.
- Both NTZ and FTY demonstrated significant reductions in relapse rates and new MRI lesions.
- Patients treated in 2015 showed substantial improvements in relapse rates and disability scores compared to those treated in 2005.
Conclusions:
- Highly active disease is common in pediatric MS.
- Natalizumab and fingolimod are effective treatments for pediatric MS, with outcomes comparable to or better than those in adult populations.
- Current treatment modalities have markedly improved the clinical course of pediatric MS.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
01:26Pharmaceutical Poisoning: Treatment Strategies
52
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
52
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
302
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276